G1 Therapeutics Statistics
Total Valuation
G1 Therapeutics has a market cap or net worth of $378.17 million. The enterprise value is $365.40 million.
| Market Cap | 378.17M |
| Enterprise Value | 365.40M |
Important Dates
The last earnings date was Wednesday, October 30, 2024, before market open.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
G1 Therapeutics has 52.89 million shares outstanding. The number of shares has increased by 8.23% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 52.89M |
| Shares Change (YoY) | +8.23% |
| Shares Change (QoQ) | +0.58% |
| Owned by Insiders (%) | 2.44% |
| Owned by Institutions (%) | 38.25% |
| Float | 39.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.40 |
| Forward PS | 4.71 |
| PB Ratio | 15.32 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.48, with a Debt / Equity ratio of 1.95.
| Current Ratio | 2.48 |
| Quick Ratio | 1.97 |
| Debt / Equity | 1.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.24 |
Financial Efficiency
Return on equity (ROE) is -109.01% and return on invested capital (ROIC) is -25.45%.
| Return on Equity (ROE) | -109.01% |
| Return on Assets (ROA) | -19.20% |
| Return on Invested Capital (ROIC) | -25.45% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | $581,950 |
| Profits Per Employee | -$447,700 |
| Employee Count | 100 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 0.42 |
Taxes
In the past 12 months, G1 Therapeutics has paid $1.81 million in taxes.
| Income Tax | 1.81M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +364.29% in the last 52 weeks. The beta is 1.68, so G1 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | +364.29% |
| 50-Day Moving Average | 5.75 |
| 200-Day Moving Average | 4.06 |
| Relative Strength Index (RSI) | 84.39 |
| Average Volume (20 Days) | 1,504,358 |
Short Selling Information
The latest short interest is 3.41 million, so 6.45% of the outstanding shares have been sold short.
| Short Interest | 3.41M |
| Short Previous Month | 4.39M |
| Short % of Shares Out | 6.45% |
| Short % of Float | 8.69% |
| Short Ratio (days to cover) | 1.01 |
Income Statement
In the last 12 months, G1 Therapeutics had revenue of $58.20 million and -$44.77 million in losses. Loss per share was -$0.86.
| Revenue | 58.20M |
| Gross Profit | 52.05M |
| Operating Income | -37.88M |
| Pretax Income | -42.96M |
| Net Income | -44.77M |
| EBITDA | -37.39M |
| EBIT | -37.88M |
| Loss Per Share | -$0.86 |
Balance Sheet
The company has $60.73 million in cash and $47.96 million in debt, giving a net cash position of $12.77 million or $0.24 per share.
| Cash & Cash Equivalents | 60.73M |
| Total Debt | 47.96M |
| Net Cash | 12.77M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 24.59M |
| Book Value Per Share | 0.47 |
| Working Capital | 55.42M |
Cash Flow
| Operating Cash Flow | -37.54M |
| Capital Expenditures | n/a |
| Free Cash Flow | -37.54M |
| FCF Per Share | -$0.71 |
Margins
Gross margin is 89.44%, with operating and profit margins of -65.09% and -76.93%.
| Gross Margin | 89.44% |
| Operating Margin | -65.09% |
| Pretax Margin | -73.83% |
| Profit Margin | -76.93% |
| EBITDA Margin | -64.25% |
| EBIT Margin | -65.09% |
| FCF Margin | -64.51% |
Dividends & Yields
G1 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.23% |
| Shareholder Yield | -8.23% |
| Earnings Yield | -11.84% |
| FCF Yield | -9.93% |
Analyst Forecast
The average price target for G1 Therapeutics is $3.50, which is -51.05% lower than the current price. The consensus rating is "Buy".
| Price Target | $3.50 |
| Price Target Difference | -51.05% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 15.49% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
G1 Therapeutics has an Altman Z-Score of -10.12 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.12 |
| Piotroski F-Score | 2 |